Endonovo Therapeutics (Endonovo Therapeutics) 3-Year Dividend Growth Rate : 0.00% (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Endonovo Therapeutics 3-Year Dividend Growth Rate?

Endonovo Therapeutics's Dividends per Share for the three months ended in Dec. 2023 was $0.00.

The historical rank and industry rank for Endonovo Therapeutics's 3-Year Dividend Growth Rate or its related term are showing as below:

ENDV's 3-Year Dividend Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 14.15
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Endonovo Therapeutics's Dividend Payout Ratio for the three months ended in Dec. 2023 was 0.00. As of today, Endonovo Therapeutics's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Endonovo Therapeutics's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, Endonovo Therapeutics's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Endonovo Therapeutics's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Endonovo Therapeutics's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Endonovo Therapeutics's 3-Year Dividend Growth Rate falls into.

Endonovo Therapeutics 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Endonovo Therapeutics (OTCPK:ENDV) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Endonovo Therapeutics's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	0
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Endonovo Therapeutics 3-Year Dividend Growth Rate Related Terms>

Endonovo Therapeutics (Endonovo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Endonovo Therapeutics Inc (OTCPK:ENDV) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367

Website

https://www.endonovo.com

Endonovo Therapeutics Inc is an us-based biotechnology company that focuses on the business of biomedical research and development, particularly in regenerative medicine, which has included the development of its proprietary square waveform device. It is engaged in developing the Immunotronics platform which is non-implantable, a non-invasive medical device to target inflammatory conditions in vital organs; and the Cytotronics platform which uses Time-Varying Electromagnetic Fields technology for the creation of cell-based therapies. The company generates its revenue through its technology licensing and commercialization activities.

Executives

Alan Brian Collier	director, 10 percent owner, officer: CEO	6320 CANOGA AVENUE, 15TH FLOOR, WOODLAND HILLS CA 91367
Michael Scott Mann	10 percent owner, officer: President	6320 CANOGA AVENUE, WOODLAND HILLS CA 91367